DelveInsight’s “Celiac Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Celiac Disease pipeline landscapes. It comprises Celiac Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Celiac Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Celiac Disease pipeline products.
Some of the key takeaways of the Celiac Disease Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as ImmunoGenX, 9Meters Biopharma, Cour Pharmaceutical/ Takeda, Provention Bio, Falk Pharma and Zedira, Precigen ActoBio, Takeda, etc., are developing therapies for the treatment of Celiac Disease.
Emerging therapies such as Latiglutenase (IMGX003), Larazotide Acetate, CNP-101/ TAK-101, PRV-015 (AMG 714), ZED1227, AG017, TAK-062, are expected to have a significant impact on the Celiac Disease market in the coming years.
The market size of Celiac Disease in the seven major markets was discovered to be USD 1,242.8 Million in 2017.
Get an overview of pipeline landscape @ Celiac Disease Clinical Trials Analysis
Celiac disease is an autoimmune disease that’s triggered once you eat gluten. It’s also called celiac sprue, nontropical sprue, or gluten-sensitive enteropathy. Gluten is a protein in wheat, rye, and other grains. It’s what makes dough elastic and provides bread with its chewy texture.
Celiac Disease Emerging Drugs
Latiglutenase (IMGX003) by ImmunoGenX
Larazotide Acetate by 9 Meters Biopharma
CNP-101/ TAK-101 by Cour Pharmaceutical/ Takeda
PRV-015 (AMG 714) by Provention Bio
ZED1227 by Falk Pharma and Zedira
AG017 by Precigen ActoBio
TAK-062 by Takeda
And others.
Scope of Celiac Disease Pipeline Drug Insight
Coverage: Global
Major Players: ImmunoGenX, 9Meters Biopharma, Cour Pharmaceutical/ Takeda, Provention Bio, Falk Pharma and Zedira, Precigen ActoBio, Takeda, and others.
Pipeline Therapies: Latiglutenase (IMGX003), Larazotide Acetate, CNP-101/ TAK-101, PRV-015 (AMG 714), ZED1227, AG017, TAK-062, and others.
Table of Contents
1
Celiac Disease Report Introduction
2
Celiac Disease Executive Summary
3
Celiac Disease Overview
4
Celiac Disease- Analytical Perspective In-depth Commercial Assessment
5
Celiac Disease Pipeline Therapeutics
6
Celiac Disease Late Stage Products (Phase II/III)
7
Celiac Disease Mid Stage Products (Phase II)
8
Celiac Disease Early Stage Products (Phase I)
9
Celiac Disease Preclinical Stage Products
10
Celiac Disease Therapeutics Assessment
11
Celiac Disease Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Celiac Disease Key Companies
14
Celiac Disease Key Products
15
Celiac Disease Unmet Needs
16
Celiac Disease Market Drivers and Barriers
17
Celiac Disease Future Perspectives and Conclusion
18
Celiac Disease Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Celiac Disease Drugs Pipeline Report
Related Reports:
Celiac Disease Market
DelveInsight’s Celiac Disease – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Celiac Disease Epidemiology
DelveInsight’s ‘ Celiac Disease- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Celiac Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/